RANKL Inhibition and the Risk of Ocular Hypertension and Primary Open-Angle Glaucoma
Investigative Ophthalmology & Visual Science · 2026
DOI: 10.1167/iovs.67.6.8 ↗At a glance
Multizentrische Studie in Investigative Ophthalmology & Visual Science, 2026. Written by Chien-Yun Tsai and 7 co-authors. Institution: School of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan. Major MEDLINE topics: Bone Density Conservation Agents, Denosumab, Glaucoma, Open-Angle, Ocular Hypertension. 47 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
Purpose
To investigate whether the receptor activator of NF-κB ligand (RANKL) inhibitor denosumab is associated with a lower risk of developing ocular hypertension (OHT) and primary open-angle glaucoma (POAG) compared with bisphosphonate therapy in patients with osteoporosis.
Methods
We conducted a multinational, retrospective cohort study using the TriNetX network from 2013 to 2023. Adults 40 years or older with osteoporosis who received denosumab were propensity score matched 1:1 to those receiving bisphosphonates. The primary outcomes were incident OHT and POAG within 5 years. Cox proportional hazards models estimated hazard ratios (HRs) with 95% confidence intervals (CIs). Sensitivity analyses included extending follow-up to 10 years, requiring an ophthalmology visit to strengthen diagnostic validity, and adjusting for additional cardiometabolic medications. Subgroup analyses further stratified participants by age, sex, race, diabetes, and corticosteroid use.
Results
After 1:1 propensity score matching, a total of 94,624 patients (47,312 in each cohort) were included in each cohort. Compared with bisphosphonate therapy, denosumab use was associated with a significantly lower risk of developing OHT (HR = 0.72; 95% CI, 0.59-0.88) and POAG (HR = 0.63; 95% CI, 0.53-0.75). These associations remained robust across all sensitivity analyses and were consistently observed across major patient subgroups.
Conclusions
Among adults with osteoporosis, denosumab use was associated with significantly lower risks of OHT and POAG compared with bisphosphonate therapy. These findings highlight the potential ocular relevance of RANKL inhibition and support further investigation into its clinical implications through prospective studies.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- School of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
- Department of Ophthalmology, Taichung Veterans General Hospital, Taichung, Taiwan.
- Department of Family Medicine, Brown University Warren Alpert Medical School, Providence, Rhode Island, United States.
- Brown University Health, Providence, Rhode Island, United States.
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.
- Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan.
Cite
APA
Tsai, C. Y., Weng, C. H., Sheen, Y. J., Chen, J. P., Chen, H. M., Tsai, C. Y., Wang, I. J., & Chou, C. C. (2026). RANKL Inhibition and the Risk of Ocular Hypertension and Primary Open-Angle Glaucoma. Investigative Ophthalmology & Visual Science. https://doi.org/10.1167/iovs.67.6.8
Vancouver
Tsai CY, Weng CH, Sheen YJ, Chen JP, Chen HM, Tsai CY, et al. RANKL Inhibition and the Risk of Ocular Hypertension and Primary Open-Angle Glaucoma. Investigative Ophthalmology & Visual Science. 2026. doi:10.1167/iovs.67.6.8
BibTeX
@article{Tsai2026,
author = {Tsai, Chien-Yun and Weng, Chien-Hsiang and Sheen, Yi Jing and Chen, Jun-Peng and Chen, Hsian-Min and Tsai, Ching-Yao and Wang, I-Jong and Chou, Chien-Chih},
title = {RANKL Inhibition and the Risk of Ocular Hypertension and Primary Open-Angle Glaucoma},
journal = {Investigative Ophthalmology & Visual Science},
year = {2026},
doi = {10.1167/iovs.67.6.8}
}
EUVIMED